What Acupan Treats: Main Uses and Benefits

Acupan (Nefopam) supports symptomatic relief across domains characterized by significant discomfort, and it may be applied as a non-opioid component in comprehensive pain management. The active ingredient is indicated for the relief of both acute and chronic pain.

---

Acupan is relevant for easing symptoms of moderate to severe acute pain following trauma or surgery, and for discomfort associated with persistent pain conditions like chronic musculoskeletal pain and pain related to malignancy. It is commonly used when supportive symptomatic assistance is needed for pain that is currently insufficient or less appropriate for standard non-opioid options. This non-narcotic role is considered relevant in multimodal strategies, playing a role in managing reduced reliance on opioid analgesics for symptomatic control. Furthermore, it is used for managing symptoms of increased neurological or muscular activity, such as post-anaesthetic shivering.

“Acupan offers symptomatic relief that is appropriate in contexts involving increased discomfort, helping to ease the overall symptom burden.”

Quick Fact: Symptomatic Support Acupan is generally used to address symptom clusters that may become intense or disruptive, supporting patients during difficult episodes by easing distress, which may assist with maintaining functional stability.

---

Who Can and Cannot Use Acupan?

Acupan (nefopam) eligibility is strictly defined by regulatory authorities to exclude populations with specific pre-existing conditions and age constraints. Most adults who do not possess these contraindications are permitted to use the medicine.

---

Absolute Contraindications

Condition / Population	Regulatory Status
History of convulsive disorders or epilepsy	Contraindicated
Known hypersensitivity to nefopam	Contraindicated
Concurrent use of Monoamine Oxidase Inhibitors (MAOIs)	Contraindicated
Risk of acute angle-closure glaucoma or urinary retention	Contraindicated
Children under 12 years	Contraindicated

---

Conditional Restrictions and Not Recommended Use

Condition / Population	Regulatory Status
Pregnancy or Breastfeeding Mothers	Not Recommended
Patients with non-severe hepatic or renal impairment	Use with Caution
Older Adults	Use with Caution (reduced dose advised)
Adolescents (12-17 years)	Use Not Recommended
Patients with pre-existing cardiovascular conditions	Use with Caution

Regulatory documents also state that Acupan is not for use in treating pain from myocardial infarction due to a lack of clinical experience in that specific setting.

Acupan (Nefopam) interactions are strictly documented by regulatory authorities, focusing on pharmacodynamic risk and administration constraints.

Contraindicated and High-Risk Combinations

Co-administration with Monoamine Oxidase (MAO) Inhibitors is a formally contraindicated combination due to the risk of severe outcomes, including serotonin toxicity or hypertensive crisis. Similarly, combining Acupan with other agents that increase serotonin availability, such as SSRIs or Tricyclic Antidepressants, risks serotonin syndrome.

Reinforced Central Effects

The product's central nervous system (CNS) activity means co-use with other CNS Depressants (e.g., benzodiazepines, morphinics) may lead to a clinically significant increase in central depress. Additive effects are also documented with agents that have anticholinergic or sympathomimetic activity. Furthermore, the consumption of alcohol is an unadvisable association that reinforces the sedative effect, and its absorption must be avoided.

Procedural and Clearance Notes

Specific restrictions apply to the injectable form, where it is mandated to avoid mixing Acupan with other injectable drugs in the same syringe. The drug may interfere with laboratory screening tests for opioids and benzodiazepines, potentially causing false positive results. Finally, in the presence of hepatic or renal insufficiency, regulatory documents note that impaired metabolism and excretion may lead to the accumulation of the medicine or its metabolites.

Dual Action on Central Neurotransmitters and Inhibitory Control

Acupan (Nefopam) is a molecule with a non-opioid, non-narcotic central mechanism that works exclusively in the Central Nervous System (CNS) through a multimodal mechanism. It primarily functions by acting as an inhibitor of the reuptake of two key signaling molecules: Serotonin (5-HT) and Norepinephrine (NA), achieved by blocking their respective transporters (SERT and NET). This molecular action increases the concentration of these monoamines in the synaptic space, thereby amplifying the activity of the body's Descending Pain Modulation (DPM) System. This engagement of the DPM system enhances the suppression of ascending signals.

---

Modulating Neuronal Excitability and Central Sensitization

A separate but simultaneous component of Nefopam’s mechanism involves direct interaction with the electrical and chemical signaling processes of central neurons. The molecule acts as a noncompetitive blocker of the NMDA receptor and inhibits voltage-gated sodium and calcium channels. These actions stabilize the membranes of central nerve cells, limiting their ability to fire excessively. The resulting physiological effect is the active attenuation of central sensitization—a process where neurons become hyper-responsive to continuous signals—which reduces overactive signal processing.

How Acupan is Used: Official Administration Guidelines

Acupan (nefopam hydrochloride) is administered through three primary, officially approved methods: oral ingestion using tablets, intramuscular (IM) injection, and slow intravenous (IV) infusion using the solution for injection. The standard dosing and usage protocols are strictly defined by regulatory documents.

---

Standard Dosage and Frequency

Route	Standard Dose Range	Maximum Daily Dose	Frequency
Oral	30 mg to 90 mg per dose	270 mg	Three times daily (TID)
Parenteral (IM/IV)	20 mg per dose	120 mg	Every 4 or 6 hours as needed

The course of treatment with oral tablets is officially limited to 7 days, except when used in the context of cancer pain.

---

Specific Administration Requirements

The tablets may be taken with or without food and should be swallowed whole with water. The injectable solution requires specific procedural steps for IV use:

• Preparation: The 20 mg dose must be diluted using an appropriate intravenous fluid, such as isotonic sodium chloride or glucose solution.
• Rate: The diluted solution must be given as a slow intravenous infusion lasting a minimum of 15 minutes.
• Procedural Caution: The solution for injection should not be mixed with any other drugs in the same syringe.

---

Dosing Adjustments

Official guidelines mandate dose modifications for certain populations. For older adults, the starting dosage is required to be reduced and should generally not exceed 30 mg three times daily. Dose adjustments are also required for patients with terminal renal insufficiency. Use is not recommended for children under 12 years of age.

Research Evidence / Overview of Studies for Acupan

---

Research Evidence for Relief of Acute Pain

Acupan (Nefopam) was studied for use related to acute pain, such as the discomfort felt after surgery or trauma, primarily relying on short-term Randomized Controlled Trials (RCTs). These RCTs research examined Acupan against a placebo or other established pain medications in adult patients. Researchers focused on two main outcomes related to physical discomfort: patient-reported pain intensity scores and the total consumption of opioid medication (like morphine).

When Acupan was observed in these studies, findings describe patterns observed in the studies, such as changes measured in pain intensity compared to placebo. The research also explored outcomes related to total consumption of opioid medication over the first 24 to 48 hours in patients observed with Acupan versus control groups.

---

Research Evidence for Managing Persistent and Chronic Pain

Acupan was studied for use in conditions characterized by persistent pain that lasts for extended periods, such as chronic musculoskeletal pain. The evidence quality varies across studies for chronic pain, where the supporting trials are often smaller. Research describes patterns observed during the study period, such as changes in persistent pain scores. In some trials, research highlights changes measured during the study period, but findings were mixed or showed inconsistent patterns when compared directly to standard medications used for chronic pain management.

Consequently, certainty remains low for this use. The sample sizes were modest in many trials, and data are still emerging.

---

Evidence in Specific Patient Populations and Uncertainty

Most primary clinical evidence for Acupan has focused on the general adult population. Data is limited from dedicated trials in the pediatric population (children) or for use in pregnancy-related populations. Data for certain groups remain insufficient, such as the very elderly or patients with certain major comorbidities.

Across the entire research landscape, long-term effects are not fully established for any approved indication, meaning the durability of any observed pattern beyond a few weeks is unclear. The results for acute pain, while numerous, can be heterogeneous, meaning that the findings were mixed across different settings, making it difficult to generalize the observed patterns.

Key Studies & References

1. Assessment of Nefopam for Analgesic and Opioid-Sparing Effects in the Management of Postoperative Pain: A Systematic Review and Meta-analysis.

Common questions about Acupan (FAQ)

Q: How quickly does Acupan start working after taking it?

Regulatory documents describe Acupan as an analgesic with a rapid onset of action. Following oral use, the medicine’s concentration in the bloodstream typically reaches its maximum level within 1frac12 to 2 hours.

Q: How long does the effect of Acupan typically last?

The duration of the medicine’s effects is often discussed by measuring its half-life, which is the time it takes for half of the substance to be eliminated from the plasma. This period is approximately 4 to 6 hours. This time frame is based on the drug's established pharmacokinetic data.

Q: Does Acupan cause drowsiness that might affect driving?

Official safety information lists somnolence (drowsiness) and dizziness as very common side effects. Official guidelines contain a warning that patients should not drive or operate heavy machinery until they have determined the effects of the medicine on their own alertness.

Q: Are there common mental side effects reported with Acupan use?

Officially documented effects on the central nervous system include insomnia (difficulty sleeping) and confusion. These are classified as Common reactions in regulatory safety documents.

Q: Is it normal to feel a dry mouth while taking Acupan?

Yes, dry mouth is a symptom listed in official documents as a Common adverse reaction. This effect is classified in the regulatory safety profile as Common, occurring in greater than 1 in 100 patients.

Q: Can Acupan cause problems with urination?

Official documents list urinary retention as a Common adverse reaction. Urinary retention is a medical term for difficulty passing urine. Official documents also note that caution is required in patients prone to conditions like prostatic hypertrophy due to this risk.

Q: Can Acupan be used alongside paracetamol (acetaminophen)?

Some regulatory-based sources indicate that Acupan can be used in combination with everyday painkillers such as paracetamol (acetaminophen). However, caution is noted regarding potential metabolic interference in cases of an overdose of either medicine.

Q: How does Acupan get eliminated from the body?

The medicine is primarily metabolized (broken down) by the liver. Both the medicine and its byproducts are then chiefly excreted (removed) from the body in the urine.

Q: Do official sources describe Acupan as a muscle relaxant?

No. Official sources classify Acupan as a Centrally acting analgesic, which means it works in the brain and spinal cord to relieve pain. It is not officially classified as a muscle relaxant.

Q: What happens if I miss a scheduled dose of Acupan?

Regulatory advice for oral tablets is to take the missed dose as soon as it is remembered, unless it is almost time for the next scheduled dose. If so, regulatory advice indicates that the missed dose should be skipped to maintain the correct interval between doses.

Q: Are there any specific foods or drinks to avoid while using Acupan?

Regulatory documents specifically state that the consumption of alcohol must be avoided. This is because alcohol can increase or reinforce the sedative effects of the medicine. No specific non-alcoholic foods or other drinks are formally restricted in the product labeling.

Q: Can Acupan be used if you have kidney problems?

Official documents indicate that use is generally permitted with caution in patients with non-severe renal impairment (kidney problems). Dose adjustments are mandated for those with more severe renal insufficiency, and some regulatory authorities list severe renal failure as a contraindication.

Q: Can Acupan be used if I have high blood pressure?

The medicine should be used cautiously in patients who have hypertension (high blood pressure) or other pre-existing cardiovascular conditions. This caution is related to the possibility of the drug exhibiting sympathomimetic activity.

Q: What types of allergic reactions are reported with Acupan?

Officially documented hypersensitivity reactions range from general skin reactions such as rash or hives. Serious, though uncommon, events include severe allergic reactions like angioedema (swelling) and anaphylactic shock.

Q: Is Acupan used for chronic pain management?

The main official indication for Acupan is the relief of acute pain (short-term, sudden pain). While medical studies have explored its use in persistent pain conditions, the regulatory certainty and evidence for chronic application are described as low.

Q: Can Acupan affect my balance or coordination?

Side effects of the medicine commonly include dizziness and light-headedness. The occurrence of these effects means that a person’s balance and coordination may be potentially affected.

Q: Is Acupan a long-term or short-term pain treatment?

The course of treatment with oral tablets is officially limited to 7 days, except when the medicine is used in the context of cancer pain. Furthermore, long-term safety and effects for any approved use are not yet fully established in regulatory data.

Q: Do studies support the use of Acupan for specific types of nerve pain?

Research has studied Acupan's effects in specific models, including those related to neuropathic pain (or nerve pain). However, the medicine's official regulatory indications focus solely on acute pain relief.

Q: How does the structure of Acupan differ from morphine?

Acupan is not structurally related to morphine, as it is a synthetic medicine derived from a benzoxazocine structure. It is explicitly classified as a non-opioid analgesic with a unique mechanism of action.

Q: Can Acupan interfere with anesthesia or pre-surgery medications?

The product’s central nervous system (CNS) activity means co-use with other CNS Depressants can lead to an additive increase in central depressant effects. This must be taken into account when using pre-surgery medications or anesthesia.

Q: What is the typical time it takes for Acupan to be fully out of the system?

The majority of the administered dose of the medicine is typically eliminated from the body within 24 hours. This time frame is based on the elimination process and the plasma half-life of 4 to 6 hours.

Q: Can Acupan make people feel restless or agitated?

The official safety profile mentions feeling nervous. Agitation is a reaction documented specifically as a symptom of toxicity in overdose, not typically associated with normal use of the medicine.

How to Store and Dispose of Acupan (Nefopam Hydrochloride)

Storage and disposal instructions for Acupan are defined by official regulatory labeling to maintain product stability and safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store below 25 C (applies to the injection).
Light Protection	Must be kept in the original carton to protect the product from light.
Container Rule	Store in the original outer packaging.
Stability Limit	Do not use the medicine after the expiry date shown on the packaging.

Child Safety and Disposal

The medicine must be kept out of the sight and reach of children at all times. Disposal of any unused medicinal product or waste material must be carried out in accordance with local requirements for pharmaceutical waste.